When close to half the companies in Hong Kong have price-to-earnings ratios (or “P/E’s”) below 11x, you may consider Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) as a stock to potentially avoid with its 14.9x P/E ratio. However, the P/E might be high for a reason and it requires further investigation to determine if it’s justified.
Shanghai Haohai Biological Technology hasn’t been tracking well recently as its declining earnings compare poorly to other companies, which have seen some growth on average. It might be that many expect the dour earnings performance to recover substantially, which has kept the P/E from collapsing. If not, then existing shareholders may be extremely nervous about the viability of the share price.
View our latest analysis for Shanghai Haohai Biological Technology
